OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
Stocks in this Quantisnow insightHealth Care
Historical context for OSTX
Across the 28 sessions after earlier OSTX headlines, the stock closed higher 17 times and lower 10 times, with a median move of 4.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | OSTX | SPY |
|---|---|---|---|
| Jun 2, 2026 | OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma | -2.1% | +0.1% |
| May 29, 2026 | OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World | +8.1% | +0.2% |
| May 26, 2026 | OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences | +1.2% | +0.7% |
| May 18, 2026 | OS Therapies Reports First Quarter 2026 Financials and Provides Business Updateand 1 other headline that session | -8.0% | -0.1% |
| May 14, 2026 | OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor | +5.0% | +0.8% |
| Apr 30, 2026 | OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma | +4.3% | +1.0% |
Quantisnow market dataAMEX
OSTX
OS Therapies Incorporated
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2024
Get push alerts for OSTX
Full OSTX profile on Quantisnow Follow OSTX and get a push notification the moment its next story breaks.